GlassScriptPhysician profile
Blake A Cover
NPI 1225484934
$3,112.27
in general payments reported to CMS, 2019-2025
37 companies · $657 in 2025
The $657 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $374 · 2021: $719 · 2022: $292 · 2023: $620 · 2024: $451 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,727.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $440.91 | 2020-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $375.22 | 2021-2025 | Vraylar |
| Lilly USA, LLC | $258.47 | 2020-2025 | Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $232.34 | 2020-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $213.12 | 2020-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $206.16 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $152.55 | 2020-2025 | Evenity, Prolia, Prolia |
| Sanofi-Aventis U.S. LLC | $118.84 | 2020-2022 | |
| Dexcom, INC. | $89.32 | 2023-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $83.84 | 2023-2024 | Veozah, Myrbetriq |
| Medtronic, INC. | $80.41 | 2022-2024 | Corevalve Evolut R |
| Neurocrine Biosciences, INC. | $68.78 | 2023-2025 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $63.16 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $62.99 | 2025 | Eliquis, Camzyos, Cobenfy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.10 | 2020-2024 | Tradjenta, Jardiance, Synjardy |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Cover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.